MARKET

CYPH

CYPH

Cypherpunk Technologies Inc
NASDAQ
1.123
+0.053
+4.93%
Opening 14:13 08/20 EDT
OPEN
1.150
PREV CLOSE
1.070
HIGH
1.250
LOW
1.050
VOLUME
8.06M
TURNOVER
--
52 WEEK HIGH
3.700
52 WEEK LOW
0.2600
MARKET CAP
121.00M
P/E (TTM)
-10.8065
1D
5D
1M
3M
1Y
5Y
1D
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 1d ago
Analysts Offer Insights on Financial Companies: WisdomTree (WT), Cypherpunk Technologies (CYPH) and FS KKR Capital (FSK)
TipRanks · 1d ago
Cypherpunk Technologies Price Target Raised to $1.60/Share From $0.90 by Cantor Fitzgerald
Dow Jones · 1d ago
Cypherpunk Technologies Is Maintained at Overweight by Cantor Fitzgerald
Dow Jones · 1d ago
Cantor Fitzgerald Maintains Overweight on Cypherpunk Technologies, Raises Price Target to $1.6
Benzinga · 1d ago
Cypherpunk Technologies Launches Major Zcash Mining Fleet
TipRanks · 2d ago
Cypherpunk Technologies announces launch of Cypherpunk Mining
TipRanks · 2d ago
Weekly Report: what happened at CYPH last week (0810-0814)?
Weekly Report · 3d ago
More
About CYPH
Cypherpunk Technologies Inc., formerly Leap Therapeutics, Inc., is engaged in developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The Company focuses on the development of sirexatamab and FL-501 to treat patients with cancer. Zcash is a privacy-preserving blockchains, launched as a fork of Bitcoin with advanced cryptography that enables selective transparency. Zcash has introduced privacy technology through the use of zero-knowledge proofs (zk-SNARKs), allowing transactions to be verified without revealing sender, receiver, or amount. FL-501 is a potential class antibody designed to neutralize GDF-15 and prevent the binding to its receptor. sirexatamab (DKN-01), is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. Sirexatamab is being developed in patients with esophagogastric, gynecologic, and colorectal cancers.

Webull offers Cypherpunk Technologies Inc stock information, including NASDAQ: CYPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYPH stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYPH stock methods without spending real money on the virtual paper trading platform.